PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients

Acta Pharmacologica Sinica

Volumn 34, Issue 12, 2013, Pages 1560-1567

  Wang, Wei Feng ^a   Xie, Yan ^a   Zhou, Zhi Hua ^b   Qin, Zheng Hong ^a   Wu, Jun Chao ^a   He, Jing Kang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b People's Liberation Army 101 Hospital   (China)

Author keywords

Esophageal cancer; Gene mutation; Methylation; Oncogene; PI3K AKT pathway; PIK3CA

Indexed keywords

GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PIK3CA PROTEIN, HUMAN; PRIMER DNA;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; ESOPHAGUS CANCER; EXON; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; PIK3CA GENE; PROTEIN EXPRESSION; WESTERN BLOTTING; ADULT; CHINA; ENZYME ACTIVATION; ENZYMOLOGY; ESOPHAGUS TUMOR; FEMALE; MALE; METABOLISM; METHYLATION; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; BASE SEQUENCE; BLOTTING, WESTERN; CHINA; DNA PRIMERS; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84901560754     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.163     Document Type: Article

References (44)

1. Chinese Center for Disease Control and Prevention, China Health statistical Summary 2012. http://www.chinacdc.cn/tjsj/gjwstjsj/201206/ W020120608368277572334.pdf, 2012.
2. Sun XB, Liu ZC, Liu SZ, Li BY, Dai DX, Quan PL, et al. Descriptive analysis of incidence and time trends of esophageal and gastric cancers in Linzhou city. Chin J Oncol 2007; 10: 764-7.
3. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 2010; 347: 21-41.
4. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24.
5. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 1997; 91: 231-41.
6. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318-21.
7. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
8. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3: 973-82.
9. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt- dependent phosphorylation of p21(Cipl) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001; 21: 5644-57.
10. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. AW promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68.
11. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 1999; 274:17179-83.
12. Phillips W, Russell SE, Ciavarella ML. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer. Int J Cancer 2006; 118: 2644-6.
13. Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, Takahashi K, et al. Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. Int J Oncol 2009; 34: 767-75.
14. Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006; 25:2950-2.
15. Liu P, Li DJ, Qin HD, Zhang RH, Chen LZ, Zeng YX. Screening for mutations in the hotspot mutation regions of PIK3CA gene in nasopharyngeal carcinama. Chin J Cancer 2007; 26:15-20.
16. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12:1441-6.
17. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110a) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17: 1331- 40.
18. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24:1477-80.
19. Wang Y, Helland A, Holm R, Kristensen GB, Barresen-Dale AL. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005; 25: 322-7.
20. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, et al. PIK3CA alterations in middle eastern ovarian cancers. Mol Cancer 2009; 8:51-63.
21. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, Deimling A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 2005; 109: 639-42.
22. Kita D, Yonekawa Y, Weller M, Ohgaki H . PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 2007; 113: 295-302.
23. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005; 11: 2875-8.
24. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64:7678-81.
25. Qiu WL, Schonleben F, Li XJ, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12:1441-6.
26. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006; 97:1351-8.
27. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68:6913-21.
28. Samuels Y, Wang Z, Bardelli A, Siiliman N, Ptak J, Szabo S, et al. High frequency mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
29. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174:1597-601.
30. Li VS, WongCW, Chan TL, Chan AS, Zhao W.Chu KM, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5:29.
31. Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010; 29: 32-6.
32. Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, et al. PIK3CA mutation Is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 2013; 19:2451-9.
33. Mori R, Ishiguro H, Kimura M, Mitsui A, Sasaki H, Tomoda K, et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res 2008; 145:320-6.
34. Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, Jang J, et al. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One 2012; 7: e41655.
35. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Circle 2004; 3:17-9.
36. Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010; 29:32-6.
37. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, et al. PIK3CA cooperates with other phosphatidylinositol 3-kinase pathway mutations to effect oncogenic transformation. Cancer Res 2008; 68:8127-36.
38. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007; 13:408-14.
39. JIANG JK, MO WG. Mutation of PIK3CA gene and expression of AKT1/2 in human colerectal cancer and their biological significance. Guangxi Med J 2010; 32: 24-7.
40. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92.
41. Kanai Y, Ushijima S, Nakanishi Y, Sakamoto M, Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett 2003; 192: 75-82.
42. Sardi I, Da-Canto M, Bartoletti R, Guazzelli R, Travaglini F, Montali E. Molecular genetic alterations of c-myc oncogene in superficial and locally advanced bladder cancer. Eur Urol 1998; 33:424-30.
43. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003; 63: 664-73.
44. Wang WF, He JK, Qin ZH, Wang J, Wu JC, Han R. Expressions of p110a and pAKT proteins in esophageal carcinoma tissues and clinical significance. Chin J Cancer Biother 2012; 19:539-42.